Skip to main content

Articles

Page 1 of 20

  1. Circulating autoantibodies and sex-dependent discrepancy in prevalence are unexplained phenomena of Alzheimer’s disease (AD). Using the 3xTg-AD mouse model, we reported that adult males show early manifestatio...

    Authors: Minesh Kapadia, M. Firoz Mian, Donglai Ma, Craig P. Hutton, Amber Azam, Klotilda Narkaj, Chuanhai Cao, Breanna Brown, Bernadeta Michalski, David Morgan, Paul Forsythe, Iva B. Zovkic, Margaret Fahnestock and Boris Sakic

    Citation: Alzheimer's Research & Therapy 2021 13:30

    Content type: Research

    Published on:

  2. White matter hyperintensities (WMH) are frequently found in Alzheimer’s disease (AD). Commonly considered as a marker of cerebrovascular disease, regional WMH may be related to pathological hallmarks of AD, in...

    Authors: Malo Gaubert, Catharina Lange, Antoine Garnier-Crussard, Theresa Köbe, Salma Bougacha, Julie Gonneaud, Robin de Flores, Clémence Tomadesso, Florence Mézenge, Brigitte Landeau, Vincent de la Sayette, Gaël Chételat and Miranka Wirth

    Citation: Alzheimer's Research & Therapy 2021 13:29

    Content type: Research

    Published on:

  3. The brain’s dynamic spontaneous neural activity and dynamic functional connectivity (dFC) are both important in supporting cognition, but how these two types of brain dynamics evolve and co-evolve in subjectiv...

    Authors: Lingyan Liang, Yueming Yuan, Yichen Wei, Bihan Yu, Wei Mai, Gaoxiong Duan, Xiucheng Nong, Chong Li, Jiahui Su, Lihua Zhao, Zhiguo Zhang and Demao Deng

    Citation: Alzheimer's Research & Therapy 2021 13:28

    Content type: Research

    Published on:

  4. Neuroimaging studies of autosomal dominant Alzheimer’s disease (ADAD) enable characterization of the trajectories of cerebral amyloid-β (Aβ) and tau accumulation in the decades prior to clinical symptom onset....

    Authors: Justin S. Sanchez, Bernard J. Hanseeuw, Francisco Lopera, Reisa A. Sperling, Ana Baena, Yamile Bocanegra, David Aguillon, Edmarie Guzmán-Vélez, Enmanuelle Pardilla-Delgado, Liliana Ramirez-Gomez, Clara Vila-Castelar, Jairo E. Martinez, Joshua T. Fox-Fuller, Claudia Ramos, Martin Ochoa-Escudero, Sergio Alvarez…

    Citation: Alzheimer's Research & Therapy 2021 13:27

    Content type: Research

    Published on:

  5. Whether in the context of monitoring disease progression or in assessing the effects of interventions, a major challenge in dementia research is determining when an individual has undergone meaningful change i...

    Authors: Aja Louise Murray, Marlena Vollmer, Ian J. Deary, Graciela Muniz-Terrera and Tom Booth

    Citation: Alzheimer's Research & Therapy 2021 13:26

    Content type: Review

    Published on:

  6. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Julia Stockmann, Inge M. W. Verberk, Nina Timmesfeld, Robin Denz, Brian Budde, Julia Lange-Leifhelm, Philip Scheltens, Wiesje M. van der Flier, Andreas Nabers, Charlotte E. Teunissen and Klaus Gerwert

    Citation: Alzheimer's Research & Therapy 2021 13:25

    Content type: Correction

    Published on:

    The original article was published in Alzheimer's Research & Therapy 2020 12:169

  7. Recent DNA/RNA sequencing and other multi-omics technologies have advanced the understanding of the biology and pathophysiology of AD, yet there is still a lack of disease-modifying treatments for AD. A new ap...

    Authors: Yadi Zhou, Jiansong Fang, Lynn M. Bekris, Young Heon Kim, Andrew A. Pieper, James B. Leverenz, Jeffrey Cummings and Feixiong Cheng

    Citation: Alzheimer's Research & Therapy 2021 13:24

    Content type: Research

    Published on:

  8. The differential diagnosis of frontotemporal dementia (FTD) and Alzheimer’s disease (AD) is difficult due to the overlaps of clinical symptoms. Structural magnetic resonance imaging (sMRI) presents distinct br...

    Authors: Qun Yu, Yingren Mai, Yuting Ruan, Yishan Luo, Lei Zhao, Wenli Fang, Zhiyu Cao, Yi Li, Wang Liao, Songhua Xiao, Vincent C. T. Mok, Lin Shi and Jun Liu

    Citation: Alzheimer's Research & Therapy 2021 13:23

    Content type: Research

    Published on:

  9. Alzheimer’s disease (AD) cerebrospinal fluid (CSF) biomarker cutoffs from immunoassays with low interlaboratory variability in diverse ethnic groups are necessary for their use in clinics and clinical trials. ...

    Authors: Sohee Moon, Sujin Kim, Sakulrat Mankhong, Seong Hye Choi, Manu Vandijck, Vesna Kostanjevecki, Jee Hyang Jeong, Soo Jin Yoon, Kyung Won Park, Eun-Joo Kim, Bora Yoon, Hee Jin Kim, Jae-Won Jang, Jin Yong Hong, Dong-Ho Park, Leslie M. Shaw…

    Citation: Alzheimer's Research & Therapy 2021 13:22

    Content type: Research

    Published on:

  10. Association between kidney dysfunction and dementia has been studied in western cohorts, but with inconsistent conclusions which may be due to the different measurements of kidney function. We aim to verify th...

    Authors: Mengjing Wang, Ding Ding, Qianhua Zhao, Wanqing Wu, Zhenxu Xiao, Xiaoniu Liang, Jianfeng Luo and Jing Chen

    Citation: Alzheimer's Research & Therapy 2021 13:21

    Content type: Research

    Published on:

  11. Both serotonergic signalling disruption and systemic inflammation have been associated with the pathogenesis of Alzheimer’s disease (AD). The common denominator linking the two is the catabolism of the essenti...

    Authors: Luke Whiley, Katie E. Chappell, Ellie D’Hondt, Matthew R. Lewis, Beatriz Jiménez, Stuart G. Snowden, Hilkka Soininen, Iwona Kłoszewska, Patrizia Mecocci, Magda Tsolaki, Bruno Vellas, Jonathan R. Swann, Abdul Hye, Simon Lovestone, Cristina Legido-Quigley and Elaine Holmes

    Citation: Alzheimer's Research & Therapy 2021 13:20

    Content type: Research

    Published on:

  12. Due to heterogeneous clinical presentation, difficult differential diagnosis with Alzheimer’s disease (AD) and psychiatric disorders, and evolving clinical criteria, the epidemiology and natural history of fro...

    Authors: Mélanie Leroy, Maxime Bertoux, Emilie Skrobala, Elisa Mode, Catherine Adnet-Bonte, Isabelle Le Ber, Stéphanie Bombois, Pascaline Cassagnaud, Yaohua Chen, Vincent Deramecourt, Florence Lebert, Marie Anne Mackowiak, Adeline Rollin Sillaire, Marielle Wathelet, Florence Pasquier and Thibaud Lebouvier

    Citation: Alzheimer's Research & Therapy 2021 13:19

    Content type: Research

    Published on:

  13. Blood-based biomarkers for Alzheimer’s disease (AD) are highly needed in clinic practice. So far, the gold standards for AD diagnosis are brain neuroimaging and beta-amyloid peptide, total tau, and phosphoryla...

    Authors: Maria Patrícia A. Oliveira Monteiro, Danielle S. M. Salheb Oliveira, Patrícia R. Manzine, Carla M. Crispim Nascimento, Ariene A. dos Santos Orlandi, Grace A. de Oliveira Gomes, Fabiana dos Santos Orlandi, Marisa S. Zazzetta, Henrique Pott-Junior and Marcia R. Cominetti

    Citation: Alzheimer's Research & Therapy 2021 13:18

    Content type: Research

    Published on:

  14. Recent studies suggest that plasma phosphorylated tau181 (p-tau181) is a highly specific biomarker for Alzheimer’s disease (AD)-related tau pathology. It has great potential for the diagnostic and prognostic e...

    Authors: Anna Zettergren, Jodie Lord, Nicholas J. Ashton, Andrea L. Benedet, Thomas K. Karikari, Juan Lantero Rodriguez, Anniina Snellman, Marc Suárez-Calvet, Petroula Proitsi, Henrik Zetterberg and Kaj Blennow

    Citation: Alzheimer's Research & Therapy 2021 13:17

    Content type: Research

    Published on:

  15. Early study exit is detrimental to statistical power and increases the risk for bias in Alzheimer’s disease clinical trials. Previous analyses in early phase academic trials demonstrated associations between r...

    Authors: Olivia M. Bernstein, Joshua D. Grill and Daniel L. Gillen

    Citation: Alzheimer's Research & Therapy 2021 13:16

    Content type: Research

    Published on:

  16. Genome-wide association studies have identified more than 30 Alzheimer’s disease (AD) risk genes, although the detailed mechanism through which all these genes are associated with AD pathogenesis remains unkno...

    Authors: Meng-Shan Tan, Yu-Xiang Yang, Wei Xu, Hui-Fu Wang, Lin Tan, Chuan-Tao Zuo, Qiang Dong, Lan Tan, John Suckling and Jin-Tai Yu

    Citation: Alzheimer's Research & Therapy 2021 13:15

    Content type: Research

    Published on:

  17. We aimed to derive an algorithm to define the optimal proportion of patients with mild cognitive impairment (MCI) in whom cerebrospinal fluid (CSF) testing is of added prognostic value.

    Authors: Ingrid S. van Maurik, Hanneke F. M. Rhodius-Meester, Charlotte E. Teunissen, Philip Scheltens, Frederik Barkhof, Sebastian Palmqvist, Oskar Hansson, Wiesje M. van der Flier and Johannes Berkhof

    Citation: Alzheimer's Research & Therapy 2021 13:14

    Content type: Research

    Published on:

  18. Alzheimer’s disease (AD) and behavioral variant frontotemporal dementia (bvFTD) cause distinct atrophy and functional disruptions within two major intrinsic brain networks, namely the default network and the s...

    Authors: Adeline Su Lyn Ng, Juan Wang, Kwun Kei Ng, Joanna Su Xian Chong, Xing Qian, Joseph Kai Wei Lim, Yi Jayne Tan, Alisa Cui Wen Yong, Russell Jude Chander, Shahul Hameed, Simon Kang Seng Ting, Nagaendran Kandiah and Juan Helen Zhou

    Citation: Alzheimer's Research & Therapy 2021 13:13

    Content type: Research

    Published on:

  19. Alzheimer’s disease (AD) is an irreversible neurodegenerative disease characterized by the hallmark finding of cerebral amyloid deposition. Many researchers have tried to predict the existence of cerebral amyl...

    Authors: Jong-Chan Park, Keum Sim Jung, Jiyeong Kim, Ji Sung Jang, Sunghoon Kwon, Min Soo Byun, Dahyun Yi, Gihwan Byeon, Gijung Jung, Yu Kyeong Kim, Dong Young Lee, Sun-Ho Han and Inhee Mook-Jung

    Citation: Alzheimer's Research & Therapy 2021 13:12

    Content type: Research

    Published on:

  20. Attempts to associate amyloid-β (Aβ) pathogenesis with synaptic loss in Alzheimer’s disease (AD) have thus far been limited to small numbers of postmortem studies. Aβ plaque burden is not well-correlated with ...

    Authors: Ryan S. O’Dell, Adam P. Mecca, Ming-Kai Chen, Mika Naganawa, Takuya Toyonaga, Yihuan Lu, Tyler A. Godek, Joanna E. Harris, Hugh H. Bartlett, Emmie R. Banks, Victoria L. Kominek, Wenzhen Zhao, Nabeel B. Nabulsi, Jim Ropchan, Yunpeng Ye, Brent C. Vander Wyk…

    Citation: Alzheimer's Research & Therapy 2021 13:11

    Content type: Research

    Published on:

  21. Cholinesterase inhibitors (ChEIs) are an FDA-approved symptomatic treatment for patients with Alzheimer’s disease (AD). Its efficacy in patients with mild cognitive impairment (MCI), however, is controversial....

    Authors: Jung-Min Pyun, Nayoung Ryoo, Young Ho Park and SangYun Kim

    Citation: Alzheimer's Research & Therapy 2021 13:10

    Content type: Research

    Published on:

  22. Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most common form of dementia in the world. Microglia are the innate immune cells of CNS; their proliferation, activation, and surviv...

    Authors: Vincent Pons, Pascal Lévesque, Marie-Michèle Plante and Serge Rivest

    Citation: Alzheimer's Research & Therapy 2021 13:8

    Content type: Research

    Published on:

  23. Alzheimer’s disease (AD) is an intractable neurodegenerative disorder in the elderly population, currently lacking a cure. Trichostatin A (TSA), a histone deacetylase inhibitor, showed some neuroprotective rol...

    Authors: Qiang Su, Tian Li, Pei-Feng He, Xue-Chun Lu, Qi Yu, Qi-Chao Gao, Zhao-Jun Wang, Mei-Na Wu, Dan Yang and Jin-Shun Qi

    Citation: Alzheimer's Research & Therapy 2021 13:7

    Content type: Research

    Published on:

  24. Molecular tweezers (MTs) are broad-spectrum inhibitors of abnormal protein aggregation. A lead MT, called CLR01, has been demonstrated to inhibit the aggregation and toxicity of multiple amyloidogenic proteins...

    Authors: Jing Di, Ibrar Siddique, Zizheng Li, Ghattas Malki, Simon Hornung, Suman Dutta, Ian Hurst, Ella Ishaaya, Austin Wang, Sally Tu, Ani Boghos, Ida Ericsson, Frank-Gerrit Klärner, Thomas Schrader and Gal Bitan

    Citation: Alzheimer's Research & Therapy 2021 13:6

    Content type: Research

    Published on:

  25. Approximately 25% of the general population carries at least one ε4 allele of the Apolipoprotein E (APOE ε4), the strongest genetic risk factor for late onset Alzheimer’s disease. Beyond its association with late...

    Authors: Amin Gharbi-Meliani, Aline Dugravot, Séverine Sabia, Melina Regy, Aurore Fayosse, Alexis Schnitzler, Mika Kivimäki, Archana Singh-Manoux and Julien Dumurgier

    Citation: Alzheimer's Research & Therapy 2021 13:5

    Content type: Research

    Published on:

  26. Hyposmia in Alzheimer’s disease (AD) is a typical early symptom according to numerous previous clinical studies. Although amyloid-β (Aβ), which is one of the toxic factors upregulated early in AD, has been ide...

    Authors: Gowoon Son, Seung-Jun Yoo, Shinwoo Kang, Ameer Rasheed, Da Hae Jung, Hyunjun Park, Bongki Cho, Harry W. M. Steinbusch, Keun-A Chang, Yoo-Hun Suh and Cheil Moon

    Citation: Alzheimer's Research & Therapy 2021 13:4

    Content type: Research

    Published on:

  27. The memory impairments in mild cognitive impairment (MCI) can be classified into encoding (EF) and retrieval (RF) failure, which can be affected by underlying pathomechanism. We explored the differences struct...

    Authors: Su-Hyun Han, Jung-Min Pyun, Soeun Yeo, Dong Won Kang, Ho Tae Jeong, Seung Wan Kang, SangYun Kim and Young Chul Youn

    Citation: Alzheimer's Research & Therapy 2021 13:3

    Content type: Research

    Published on:

  28. As Alzheimer’s disease (AD) pathology presents decades before dementia manifests, unbiased biomarker cut-points may more closely reflect presence of pathology than clinically defined cut-points. Currently, unb...

    Authors: Flora H. Duits, Kirsten E. J. Wesenhagen, Laura Ekblad, Emma Wolters, Eline A. J. Willemse, Philip Scheltens, Wiesje M. van der Flier, Charlotte E. Teunissen, Pieter Jelle Visser and Betty M. Tijms

    Citation: Alzheimer's Research & Therapy 2021 13:2

    Content type: Research

    Published on:

  29. COVID-19 is primarily a respiratory disease but up to two thirds of hospitalised patients show evidence of central nervous system (CNS) damage, predominantly ischaemic, in some cases haemorrhagic and occasiona...

    Authors: Scott Miners, Patrick G. Kehoe and Seth Love

    Citation: Alzheimer's Research & Therapy 2020 12:170

    Content type: Review

    Published on:

  30. We evaluated Aβ misfolding in combination with Aβ42/40 ratio as a prognostic tool for future clinical progression to mild cognitive impairment (MCI) or dementia due to Alzheimer’s disease (AD) in individuals with...

    Authors: Julia Stockmann, Inge M. W. Verberk, Nina Timmesfeld, Robin Denz, Brian Budde, Julia Lange-Leifhelm, Philip Scheltens, Wiesje M. van der Flier, Andreas Nabers, Charlotte E. Teunissen and Klaus Gerwert

    Citation: Alzheimer's Research & Therapy 2020 12:169

    Content type: Research

    Published on:

    The Correction to this article has been published in Alzheimer's Research & Therapy 2021 13:25

  31. Neurogranin (Ng) is a neuron-specific and postsynaptic protein that is abundantly expressed in the brain, particularly in the dendritic spine of the hippocampus and cerebral cortex. The enzymatic cleavage of N...

    Authors: Annika Öhrfelt, Julien Dumurgier, Henrik Zetterberg, Agathe Vrillon, Nicholas J. Ashton, Hlin Kvartsberg, Elodie Bouaziz-Amar, Jacques Hugon, Claire Paquet and Kaj Blennow

    Citation: Alzheimer's Research & Therapy 2020 12:168

    Content type: Research

    Published on:

  32. Subjective cognitive decline (SCD) is recognized as a risk stage for Alzheimer’s disease (AD) and other dementias, but its prevalence is not well known. We aimed to use uniform criteria to better estimate SCD ...

    Authors: Susanne Röhr, Alexander Pabst, Steffi G. Riedel-Heller, Frank Jessen, Yuda Turana, Yvonne S. Handajani, Carol Brayne, Fiona E. Matthews, Blossom C. M. Stephan, Richard B. Lipton, Mindy J. Katz, Cuiling Wang, Maëlenn Guerchet, Pierre-Marie Preux, Pascal Mbelesso, Karen Ritchie…

    Citation: Alzheimer's Research & Therapy 2020 12:167

    Content type: Research

    Published on:

  33. Alzheimer’s disease (AD) has been a devastating public health with the development of global aging. Approaches for reducing the current AD epidemic are becoming a primary focus of human healthcare due to the l...

    Authors: Mengtian Guo, Zhenyu Yin, Fanglian Chen and Ping Lei

    Citation: Alzheimer's Research & Therapy 2020 12:109

    Content type: Review

    Published on:

  34. The LipiDiDiet trial showed that Souvenaid, a medical food, might delay progression to dementia in prodromal Alzheimer’s disease (AD). The objective of this study was to assess the cost-utility of Souvenaid co...

    Authors: Javier Mar, Ania Gorostiza, Oliver Ibarrondo, Igor Larrañaga, Arantzazu Arrospide, Pablo Martinez-Lage and Myriam Soto-Gordoa

    Citation: Alzheimer's Research & Therapy 2020 12:166

    Content type: Research

    Published on:

  35. Studies regarding the lipid-cognition relationship have increasingly gained popularity but have generated much mixed results. To date, few studies have focused on the difference between sexes.

    Authors: Lili Liu, Chen Zhang, Xiaozhen Lv, Xuefeng Lai, Lu Xu, Jingnan Feng, Yongfeng Song, Shengfeng Wang and Siyan Zhan

    Citation: Alzheimer's Research & Therapy 2020 12:164

    Content type: Research

    Published on:

  36. MicroRNAs (miRNAs) are noncoding RNAs that are highly relevant as disease biomarkers. Several studies that explored the role of miRNAs in Alzheimer’s disease (AD) demonstrated their usefulness in clinical iden...

    Authors: F. Dakterzada, A. Targa, I. D. Benítez, L. Romero-ElKhayat, D. de Gonzalo-Calvo, G. Torres, A. Moncusí-Moix, R. Huerto, M. Sánchez-de-la-Torre, F. Barbé and G. Piñol-Ripoll

    Citation: Alzheimer's Research & Therapy 2020 12:163

    Content type: Research

    Published on:

  37. Blood-based amyloid biomarkers may provide a non-invasive, cost-effective and scalable manner for detecting cerebral amyloidosis in early disease stages.

    Authors: Steffi De Meyer, Jolien M. Schaeverbeke, Inge M. W. Verberk, Benjamin Gille, Maxim De Schaepdryver, Emma S. Luckett, Silvy Gabel, Rose Bruffaerts, Kimberley Mauroo, Elisabeth H. Thijssen, Erik Stoops, Hugo M. Vanderstichele, Charlotte E. Teunissen, Rik Vandenberghe and Koen Poesen

    Citation: Alzheimer's Research & Therapy 2020 12:162

    Content type: Research

    Published on:

  38. The retina and brain share many neuronal and vasculature characteristics. We investigated the retinal microvasculature in Alzheimer’s disease (AD) and mild cognitive impairment (MCI) using optical coherence to...

    Authors: Jacqueline Chua, Qinglan Hu, Mengyuan Ke, Bingyao Tan, Jimmy Hong, Xinwen Yao, Saima Hilal, Narayanaswamy Venketasubramanian, Gerhard Garhöfer, Carol Y. Cheung, Tien Yin Wong, Christopher Li-Hsian Chen and Leopold Schmetterer

    Citation: Alzheimer's Research & Therapy 2020 12:161

    Content type: Research

    Published on:

  39. Understanding the earliest pathophysiological changes of Alzheimer’s disease (AD) may aid in the search for timely diagnostic biomarkers and effective disease-modifying therapies. The p53 protein is mostly kno...

    Authors: Giulia Abate, Giovanni B. Frisoni, Jean-Christophe Bourdon, Simona Piccirella, Maurizio Memo and Daniela Uberti

    Citation: Alzheimer's Research & Therapy 2020 12:160

    Content type: Review

    Published on:

  40. Alpha-synuclein (α-Syn) aggregation is the primary characteristic of synucleinopathies including Parkinson’s disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA). Immunotherapy targe...

    Authors: Jacqui T. Nimmo, Ajay Verma, Jean-Cosme Dodart, Chang Yi Wang, Jimmy Savistchenko, Ronald Melki, Roxana O. Carare and James A. R. Nicoll

    Citation: Alzheimer's Research & Therapy 2020 12:159

    Content type: Research

    Published on:

  41. Previous studies have shown that copy number variation (CNV) in the alpha (α)-amylase gene (AMY1A) is associated with body mass index, insulin resistance, and blood glucose levels, factors also shown to increase ...

    Authors: Elin Byman, Katarina Nägga, Anna-Märta Gustavsson, Johanna Andersson-Assarsson, Oskar Hansson, Emily Sonestedt and Malin Wennström

    Citation: Alzheimer's Research & Therapy 2020 12:158

    Content type: Research

    Published on:

  42. To investigate the association between pineal gland volume and symptoms of rapid eye movement (REM) sleep behavior disorder (RBD) in Alzheimer’s disease (AD) patients without any feature of dementia with Lewy ...

    Authors: Jeongbin Park, Seung Wan Suh, Grace Eun Kim, Subin Lee, Jun Sung Kim, Hye Sung Kim, Seonjeong Byun, Jong Bin Bae, Jae Hyoung Kim, Sang Eun Kim, Ji Won Han and Ki Woong Kim

    Citation: Alzheimer's Research & Therapy 2020 12:157

    Content type: Research

    Published on:

  43. Although the heritability of sporadic Alzheimer’s disease (AD) is estimated to be 60–80%, addressing the genetic contribution to AD risk still remains elusive. More specifically, it remains unclear whether gen...

    Authors: Jieun Seo, Min Soo Byun, Dahyun Yi, Jun Ho Lee, So Yeon Jeon, Seong A. Shin, Yu Kyeong Kim, Koung Mi Kang, Chul-Ho Sohn, Gijung Jung, Jong-Chan Park, Sun-Ho Han, Jayoung Byun, Inhee Mook-Jung, Dong Young Lee and Murim Choi

    Citation: Alzheimer's Research & Therapy 2020 12:156

    Content type: Research

    Published on:

  44. Amyloid-β (Aβ) PET is an established predictor of conversion from mild cognitive impairment (MCI) to Alzheimer’s dementia (AD). We compared three PET (including an approach based on voxel-wise Cox regression) ...

    Authors: Arnd Sörensen, Ganna Blazhenets, Florian Schiller, Philipp Tobias Meyer and Lars Frings

    Citation: Alzheimer's Research & Therapy 2020 12:155

    Content type: Research

    Published on:

  45. Obtaining reliable estimates of the health-related quality of life (HR-QoL) of people with predementia Alzheimer’s disease [AD] (preclinical or prodromal AD), mild cognitive impairment (MCI) and dementia is es...

    Authors: Filipa Landeiro, Seher Mughal, Katie Walsh, Elsbeth Nye, Jasmine Morton, Harriet Williams, Isaac Ghinai, Yovanna Castro, José Leal, Nia Roberts, Helena Wace, Ron Handels, Pascal Lecomte, Anders Gustavsson, Emilse Roncancio-Diaz, Mark Belger…

    Citation: Alzheimer's Research & Therapy 2020 12:154

    Content type: Review

    Published on:

  46. The underlying disease mechanism of neuropsychiatric symptoms (NPS) in dementia remains unclear. Cerebrospinal fluid (CSF) biomarkers for synaptic and axonal degeneration may provide novel neuropathological in...

    Authors: Victor Bloniecki, Henrik Zetterberg, Dag Aarsland, Patrizia Vannini, Hlin Kvartsberg, Bengt Winblad, Kaj Blennow and Yvonne Freund-Levi

    Citation: Alzheimer's Research & Therapy 2020 12:153

    Content type: Research

    Published on:

  47. A consensus protocol for genetic counselling and testing of familial dementia, the Italian Dominantly Inherited Alzheimer’s and Frontotemporal Network (IT-DIAfN) protocol, has been developed in Italy by a netw...

    Authors: Anna Mega, Samantha Galluzzi, Cristian Bonvicini, Silvia Fostinelli, Massimo Gennarelli, Cristina Geroldi, Orazio Zanetti, Luisa Benussi, Emilio Di Maria and Giovanni B. Frisoni

    Citation: Alzheimer's Research & Therapy 2020 12:152

    Content type: Research

    Published on: